Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 88

Sort by

Sort Order Select

Journal Articles

The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma

Kara I. Cicero, Alfred I. Neugut, Andrew H. Doyle, Divaya Bhutani, Amer Assal, Ran Reshef, Markus Y. Mapara, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2022) 140 (Supplement 1): 8026–8027.

https://doi.org/10.1182/blood-2022-166491

Published: 2022

Journal Articles

Transplantation of Hematopoietic Stem and Progenitor Cells from Cadaveric Organ Donors Leads to Long-Term Multilineage Engraftment in NSG Mice

Lara M Breyer, Hui Wang, Dongsheng Gu, Brian H Johnstone, Huihui Ma, Erik J Woods, Markus Y. Mapara

Blood (2022) 140 (Supplement 1): 7347–7348.

https://doi.org/10.1182/blood-2022-169787

Published: 2022

Journal Articles

Lovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study

Mark C. Walters, Alexis A. Thompson, Janet L. Kwiatkowski, Suhag Parikh, Markus Y. Mapara, Stacey Rifkin-Zenenberg, Banu Aygun, Kimberly A. Kasow, Alex Miller, Lixin Zhang, Anjulika Chawla, Elizabeth R. Macari, Francis J. Pierciey, Jr., John F. Tisdale, Julie Kanter

Blood (2022) 140 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2022-162288

Published: 2022

Journal Articles

The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Cytoskeleton Regulation and Multiple Myeloma Bone Disease

Jing Fu, Shirong Li, Huihui Ma, Jun Yang, Lewis M Brown, Gabriel M. Pagnotti, Stephen J. Weiss, Markus Y. Mapara, Suzanne Lentzsch

Blood (2022) 140 (Supplement 1): 9930–9932.

https://doi.org/10.1182/blood-2022-169921

Published: 2022

Journal Articles

MAP4K2 Inhibition Reinforces the Iberdomide Sensitivity in MM Cells By Inducing IKZF1 Degradation through a CRBN Independent Mechanism

Shirong Li, Jing Fu, Jun Yang, Huihui Ma, Markus Y. Mapara, Christophe Marcireau, Suzanne Lentzsch

Blood (2022) 140 (Supplement 1): 4224–4225.

https://doi.org/10.1182/blood-2022-168314

Published: 2022

Journal Articles

Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Blood (2022) 140 (Supplement 1): 4899–4901.

https://doi.org/10.1182/blood-2022-166881

Published: 2022

Journal Articles

Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease

Haydar Frangoul, Franco Locatelli, Monica Bhatia, Markus Y. Mapara, Lyndsay Molinari, Akshay Sharma, Stephan Lobitz, Mariane de Montalembert, Damiano Rondelli, Martin Steinberg, Mark C. Walters, Suzan Imren, Lanju Zhang, Anjali Sharma, Yang Song, Christopher Simard, William Hobbs, Stephen Grupp

Blood (2022) 140 (Supplement 1): 29–31.

https://doi.org/10.1182/blood-2022-162353

Published: 2022

Journal Articles

Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Mark C. Walters, John F. Tisdale, Markus Y. Mapara, Lakshmanan Krishnamurti, Janet L. Kwiatkowski, Banu Aygun, Kimberly A. Kasow, Stacey Rifkin-Zenenberg, Jennifer Jaroscak, Diana Garbinsky, Costel Chirila, Meghan E. Gallagher, Xinyan Zhang, Pei-Ran Ho, Alexis A. Thompson, Julie Kanter

Blood (2021) 138 (Supplement 1): 7.

https://doi.org/10.1182/blood-2021-146905

Published: 2021

Journal Articles

Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT)

Blood (2021) 138 (Supplement 1): 561.

https://doi.org/10.1182/blood-2021-147760

Published: 2021

Journal Articles

MAP4K2 Silencing Overcomes IMiDs-Resistance in Multiple Myeloma

Shirong Li, Jing Fu, Jun Yang, Huihui Ma, Markus Y. Mapara, Christophe Marcireau, Suzanne Lentzsch

Blood (2021) 138 (Supplement 1): 2662.

https://doi.org/10.1182/blood-2021-151844

Published: 2021

Journal Articles

The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Activation and Multiple Myeloma Bone Disease

Jing Fu, Shirong Li, Huihui Ma, Jun Yang, Lewis M Brown, Gabriel M. Pagnotti, Stephen J. Weiss, Markus Y. Mapara, Suzanne Lentzsch

Blood (2021) 138 (Supplement 1): 1606.

https://doi.org/10.1182/blood-2021-145599

Published: 2021

Journal Articles

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Shirong Li, Jing Fu, Jun Yang, Huihui Ma, Divaya Bhutani, Markus Y. Mapara, Christophe Marcireau, Suzanne Lentzsch

Blood (2021) 137 (13): 1754–1764.

https://doi.org/10.1182/blood.2020006334

Published: 2021

Includes: Supplemental data

Journal Articles

Gck Inhibition Is a Novel Therapeutic Strategy for RAS Mutated Multiple Myeloma and Overcomes Resistance to IMiDs

Shirong Li, Jing Fu, PhD, Jun Yang, MS, Markus Y Mapara, MD PhD, Christophe Marcireau, Suzanne Lentzsch, MD PhD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-143418

Published: 2020

Journal Articles

Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Alexis A. Thompson, MD, Mark C. Walters, MD, Markus Y Mapara, MD PhD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Banu Aygun, MD, Kimberly A. Kasow, DO, Stacey Rifkin-Zenenberg, DO, Manfred Schmidt, PhD, Jay DelCarpini, Francis J. Pierciey, Jr., Alexandra L. Miller, Meghan E. Gallagher, MSc, Ren Chen, Sunita Goyal, MD, Julie Kanter, MD, John F. Tisdale, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134940

Published: 2020

Journal Articles

Checkpoint Inhibitor PD-1H/VISTA Mediates MMP-13 Induced Osteoclast Activation and Multiple Myeloma Bone Disease

Jing Fu, PhD, Shirong Li, Huihui Ma, MD PhD, Jun Yang, MS, Gabriel M. Pagnotti, PhD, Stephen J. Weiss, MD PhD, Markus Y Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-142528

Published: 2020

Journal Articles

Glucagon-like Peptide-2 (GLP-2) Treatment Reduces Gvhd-Related Mortality in a Pre-Clinical Transplant Model Via Expansion of Macrophages with Tolerogenic Potential

David W Harle, BBiomedSc, Rodney J Macedo Gonzales, MD PhD, Felix D Rozenberg, BSc, Alexandra Matschiner, Rajat Bansal, MD, Stephen M Lagana, MD, Huihui Ma, MD PhD, Elisha Pinker, Kirubel S Belay, BSc, Ximi K Wang, BSc, Tiffany Thomas, PhD, Markus Y Mapara, MD PhD, Anne-Catrin Uhlemann, MD, Yi Zhang, MD PhD, Ran Reshef, MDMSc

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-143105

Published: 2020

Journal Articles

Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-139575

Published: 2020

Journal Articles

Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Julie Kanter, MD, John F. Tisdale, MD, Markus Y Mapara, MD PhD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Ren Chen, Meghan E. Gallagher, MSc, Yuchen Ding, PhD, Sunita Goyal, MD, Clark Paramore, MPH, Alexis A. Thompson, MD, Mark C. Walters, MD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-136193

Published: 2020

Journal Articles

Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations

Shirong Li, PhD, Jing Fu, PhD, Xiaoming Xu, PhD, Shixian Deng, PhD, Markus Y Mapara, MD PhD, Christophe Marcireau, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 1813.

https://doi.org/10.1182/blood-2019-129531

Published: 2019

Journal Articles

Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy

Mark C. Walters, MD, John F. Tisdale, MD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Markus Y. Mapara, MD PhD, Manfred Schmidt, PhD, Alexandra L. Miller, Francis J. Pierciey, Jr., Wenmei Huang, PhD MS, Jean-Antoine Ribeil, MD PhD, Julie Kanter, MD, Alexis A. Thompson, MD MPH

Blood (2019) 134 (Supplement_1): 2061.

https://doi.org/10.1182/blood-2019-128814

Published: 2019

NARROW

The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma

Transplantation of Hematopoietic Stem and Progenitor Cells from Cadaveric Organ Donors Leads to Long-Term Multilineage Engraftment in NSG Mice

Lovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study

The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Cytoskeleton Regulation and Multiple Myeloma Bone Disease

MAP4K2 Inhibition Reinforces the Iberdomide Sensitivity in MM Cells By Inducing IKZF1 Degradation through a CRBN Independent Mechanism

Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease

Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT)

MAP4K2 Silencing Overcomes IMiDs-Resistance in Multiple Myeloma

The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Activation and Multiple Myeloma Bone Disease

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Gck Inhibition Is a Novel Therapeutic Strategy for RAS Mutated Multiple Myeloma and Overcomes Resistance to IMiDs

Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Checkpoint Inhibitor PD-1H/VISTA Mediates MMP-13 Induced Osteoclast Activation and Multiple Myeloma Bone Disease

Glucagon-like Peptide-2 (GLP-2) Treatment Reduces Gvhd-Related Mortality in a Pre-Clinical Transplant Model Via Expansion of Macrophages with Tolerogenic Potential

Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells

Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations

Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only